LOOP DIURETICS: WHETHER THE WELL-ESTABLISHED STANDARD OF CARE NEEDS REFORM?


Cite item

Full Text

Abstract

The article reviews current treatment options for various versions of edema, especially in chronic heart failure and chronic kidney disease. One of the most effective approaches to stimulate diuresis in patients with edematous syndrome is the use of loop diuretics, of which the most interesting is torasemid (Diuver). Its principal advantages are presence of additional properties of aldosterone antagonists and positive impact on long-term prognosis of patients. The use of such drugs (currently available torasemide) will certainly facilitate the management of patients with chronic heart failure, chronic kidney disease, as well as most other variants of the edematous syndrome.

References

  1. Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of European Society of Cardiology. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with Heart Failure Association of ESC (HFA) and endorsed by the European Society of Intensive Care Medicine. (ESCIM). Eur Heart J 2008;29(19):2388-442.
  2. Комитет экспертов ОССН ВНОК. Национальные рекомендации по диагностике и лечению хронической сердечной недостаточности (второй пересмотр) // Сердечная недостаточность, 2005. № 2. С. 2-21.
  3. Комитет экспертов РМОАГ/ВНОК. Диагностика и лечение артериальной гипертензии. (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов) // Системные гипертензии 2010. № 3. C. 5-26.
  4. Foster MC, Hwang SJ, Larson MG, et al. Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study. Am J Kidney Dis 2008;52(1):39-48.
  5. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298(17):2038-47.
  6. Земченков А.Ю., Томилина Н.А. "К/ДОКИ" обращается к истокам хронической почечной недостаточности (О новом разделе Рекомендаций K/DOQI по диагностике, классификации и оценке тяжести хронических заболеваний почек) // Нефрология и диализ 2004. № 6(3). C. 204-20.
  7. Damman K, Jaarsma T, Voors AA, et al. COACH investigators. Both in- and out-hospital worsening of renal function predict outcome in patients with heart failure: results from the Coordinating Study Evaluating Outcome of Advising and Counseling in Heart Failure (COACH). Eur J Heart Fail 2009;11(9):847-54.
  8. Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004;43(1):61-67.
  9. Wittner M, Di Stefano A, Wangemann P, et al. How do loop diuretics act? Drugs 1991;(41):1-13.
  10. Boesken WH, Kult J. High-dose torasemide, given once daily intravenously for one week, in patients with advanced chronic renal failure. Clin Nephrol 1997;48(1):22-28.
  11. Fliser D, Schroter M, Neubeck M, et al. Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int 1994;46(2):482-88.
  12. Gehr TW, Rudy DW, Matzke GR, et al. The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency. Clin Pharmacol Ther 1994;56(1):31-38.
  13. Struthers AD. Impact of aldosterone on vascular pathophysiology. Congest Heart Fail 2002;8:18-22.
  14. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.
  15. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
  16. Goodfriend TL, Ball DL, Oelkers W, et al. Torsemide inhibits aldosterone secretion in vitro. Life Sci 1998;63(3):45-50.
  17. Yamato M, Sasaki T, Honda M, et al. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ J 2003;67:384-90.
  18. Harada K, Izawa H, Nishizawa T, et al. Beneficial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure: comparison with azosemide. J Cardiovasc Pharmacol 2009;53(6):468-73.
  19. Lopez B, Querejeta R, Gonzalez A, et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004;43(11):2028-35.
  20. Lopez B, Gonzalez A, Beaumont J, et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol 2007;50(9):859-67.
  21. Cosin J, Diez J. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002;4(4):507-13.
  22. Franse LV, Pahor M, Di Bari M, et al. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000;35:1025-30.
  23. Le Heuzey JY, Marijon E, Chachoua K, et al. Pathophysiology of atrial fibrillation: insights into the renin-angiotensin system. Arch Cardiovasc Dis 2008;101(11-12):787-91.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies